Comparative Pharmacology
Head-to-head clinical analysis: THEOLAIR SR versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOLAIR SR versus THEOVENT.
THEOLAIR-SR vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator